Loading, please wait ...


News Analytics

bb724119 468d 4b1d 8206 3c2175d07f2b?size=1.
• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety profile Allschwil, Switzerland – March 10, 2021 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of ...
Google

Subject Matter

  • Science and technology 60.00%
  • Healthcare 40.00%
    • Hospitals, doctors and medical care 100.00%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions